Skip Navigation


JAC Advance Access originally published online on January 6, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/2/463    most recent
dkg059v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fisher, L. M.
Right arrow Articles by Heaton, V. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fisher, L. M.
Right arrow Articles by Heaton, V. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 463-464
© 2003 The British Society for Antimicrobial Chemotherapy

Correspondence

Dual activity of fluoroquinolones against Streptococcus pneumoniae

L. Mark Fisher1,* and Victoria J. Heaton2

1 Molecular Genetics Group, Department of Biochemistry and Immunology, St George’s Hospital Medical School, University of London, Cranmer Terrace, London SW17 0RE; 2 Anti-Infective Marketing Group, Pharmaceutical Division, Bayer plc, Strawberry Hill, Newbury RG14 1JA, UK

Keywords: quinolones, dual activity, Streptococcus pneumoniae, gyrase, topoisomerase IV

The first 10% of the full text of this article appears below.

Sir,

A recent article by Smith et al.1 reviewed studies on the target preferences of quinolones for DNA gyrase and/or topoisomerase IV in Streptococcus pneumoniae. Previous genetic work from our laboratory has indicated that quinolones can act in vivo through gyrase, through topoisomerase IV or through both enzymes (dual activity).2,3 In particular, clinafloxacin, gemifloxacin and other new quinolones such as moxifloxacin exhibit dual activity based on the minimal effect of either gyrA . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
E. Cambau, S. Matrat, X.-S. Pan, R. Roth Dit Bettoni, C. Corbel, A. Aubry, C. Lascols, J.-Y. Driot, and L. M. Fisher
Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli
J. Antimicrob. Chemother., March 1, 2009; 63(3): 443 - 450.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Strahilevitz and D. C. Hooper
Dual Targeting of Topoisomerase IV and Gyrase To Reduce Mutant Selection: Direct Testing of the Paradigm by Using WCK-1734, a New Fluoroquinolone, and Ciprofloxacin
Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1949 - 1956.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
L. M. Fisher, K. A. Gould, X.-S. Pan, S. Patel, and V. J. Heaton
Analysis of dual active fluoroquinolones in Streptococcus pneumoniae
J. Antimicrob. Chemother., August 1, 2003; 52(2): 312 - 313.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
H. J. Smith, K. A. Nichol, D. J. Hoban, and G. G. Zhanel
Reply
J. Antimicrob. Chemother., August 1, 2003; 52(2): 313 - 314.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
K. Drlica
The mutant selection window and antimicrobial resistance
J. Antimicrob. Chemother., July 1, 2003; 52(1): 11 - 17.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
H. J. Smith, K. A. Nichol, D. J. Hoban, and G. G. Zhanel
Reply
J. Antimicrob. Chemother., February 1, 2003; 51(2): 464 - 465.
[Full Text] [PDF]